Lantern Pharma's LP-184 Gains the US FDA’s Fast-Track Designation to Treat TNBC
Shots:
- This designation is based on anti-tumor activity in 10 TNBC PDX models & LP-184 also shown consistent efficacy in both PARPi-resistant & PARPi-sensitive tumors, achieving complete tumor regression (107-141% tumor growth inhibition).
- This is a 2nd FTD designation in 2024, i.e., Lantern received FTD for Gliobastoma in October. Although data was presented at the SABCS 2022
- LP-184 is in a P-Ia study evaluating safety & tolerability for various solid tumor types, incl. TNBC. LP-184 was developed using Lantern's RADR AI platform to identify patient populations & cancer subtypes that may respond to the treatment
Ref: BusinessWire | Image: Lantern Pharma
Related News:- Lantern Pharma’s LP-184 Gains the US FDA’s Fast-Track Designation for Treating Glioblastoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies. He can be contacted at connect@pharmashots.com
